Diagnostic method for gastric cancer

    公开(公告)号:US10393747B2

    公开(公告)日:2019-08-27

    申请号:US15113006

    申请日:2014-10-22

    Abstract: This invention relates to a method for gastric cancer diagnosis through the detection of glycan changes, and to a kit for gastric cancer diagnosis. More specifically, based on the fact that in gastric cancer patient-derived haptoglobin, there are changes in N-linked glycosylation of haptoglobin, which are detected through lectin and mass spectrometery, that is, an increase in fucosylation, increases or significant changes in specific glycan structures depending on the classification of antennary structures, or a remarkable decrease in a high mannose structure of the N-glycan as compared to normal persons, N-glycan structures identified using the changes in N-linked glycosylation of haptoglobin may be usefully used as a diagnosis marker in a method for gastric cancer diagnosis using lectin or mass spectrometry, and a kit for gastric cancer diagnosis.

    Polypeptide binding to extracellular domain of epidermal growth factor receptor

    公开(公告)号:US10364293B2

    公开(公告)日:2019-07-30

    申请号:US15310585

    申请日:2015-05-21

    Abstract: The present invention relates to a polypeptide capable of binding specifically to the extracellular domain of epidermal growth factor receptor, a polynucleotide that encodes the polypeptide, an expression vector comprising the polynucleotide, a recombinant microorganism having the expression vector introduced therein, and a method of producing the polypeptide using the recombinant microorganism. The polypeptide according to the present invention can bind to the extracellular domain of epidermal growth factor receptor with a high binding affinity comparable to those of existing monoclonal antibodies that are widely used as targeted therapeutic agents, thereby inhibiting the activity of the epidermal growth factor receptor. The polypeptide is useful for the development of agents for the prevention or diseases associated with overexpression of epidermal growth factor receptor.

    Magnetic resonance imaging apparatus and control method

    公开(公告)号:US10295643B2

    公开(公告)日:2019-05-21

    申请号:US14804678

    申请日:2015-07-21

    Abstract: A magnetic resonance imaging (MRI) apparatus and a control method thereof are provided. The MRI apparatus includes a scanner, and a controller configured to control the scanner to receive magnetic resonance (MR) signals corresponding to a magnitude of a y-axis gradient magnetic field in a respiration cycle of a patient, each of the MR signals being received at a time interval equal to a time period of the respiration cycle over a number of the received MR signals. The MRI apparatus further includes a processor configured to extract an MR signal received in a respiration condition of the patient from the received MR signals, fill a k-space with the extracted MR signal, and generate an MR image by reconstructing data of the filled k-space.

    Induced pluripotent stem cell model for Fabry disease and use thereof

    公开(公告)号:US10287554B2

    公开(公告)日:2019-05-14

    申请号:US14839603

    申请日:2015-08-28

    Abstract: The present invention relates to an induced pluripotent stem cell model of Fabry disease, a preparation method thereof, and a use of the same for the study of Fabry disease development and for the screening of a therapeutic agent for the disease. Particularly, Fabry disease derived induced pluripotent stem cells (iPSCs), embryoid body (EB), and vascular cells were developed and differentiated from fibroblasts originated from Fabry disease patient, wherein the Fabry disease originated iPSCs displayed significantly reduced expression and activity of GLA protein therein, compared with the normal cells, resulting in the accumulation of globotriaosylceramide (Gb3, CD77). Also, the differentiation of vascular cells was induced from the Fabry disease originated iPSCs, and as a result the iPSCs were successfully differentiated into vascular endothelial cells and vascular smooth muscle cells with significantly expressing the marker protein. When the vascular endothelial cells and vascular smooth muscle cells were treated with Fabrazyme, the accumulation of Gb3 was significantly reduced, suggesting that the said cell model can be effectively used for the analysis/study of Fabry disease outbreak mechanism and for the screening of a therapeutic agent for the disease.

Patent Agency Ranking